Key result
Antithrombotic therapy is linked to ~150% higher risk of prolonged hospitalization in epistaxis.
Why the study?
Epistaxis can be caused or exacerbated by anticoagulant and antiplatelet therapy, but differences in clinical courses of these patients were not well characterized.
Cohort (n=290)
Relative Risk: 2.5 (95% CI 1.01–4.97)
p-value: p=0.01
No takes yet. Share an insight, caveat, or question.
Patients on anticoagulants or antiplatelets had longer stays and required more intervention; leaves open whether medication adjustment improves outcomes.
Smith et al. (2010) conducted a cohort in Epistaxis (n=290). Anticoagulant and antiplatelet medication vs. No anticoagulant or antiplatelet medication was evaluated on Longer in-patient stays (RR 2.50, 95% CI 1.01-4.97, p=0.01). Patients with epistaxis taking anticoagulant or antiplatelet medication had a significantly higher risk of requiring longer in-patient stays (RR 2.50; 95% CI 1.01-4.97; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: